Markets:

Overview

News

Currencies

International

Treasuries

Abbott Laboratories (NY:ABT)

125.08 -0.32 (-0.26%)

Official Closing Price Updated: 7:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

50 51 Next >

Beat the Nasdaq With This Cash-Gushing Dividend Stock ↗

October 23, 2024

The company is performing well despite recently losing its biggest growth driver.

Via The Motley Fool

P/E Ratio Insights for Abbott Laboratories ↗

October 22, 2024

Via Benzinga

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever ↗

October 19, 2024

These companies' longtime shareholders have generally been rewarded.

Via The Motley Fool

MarketBeat Week in Review – 10/14 - 10/18

October 19, 2024

Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election.

Via MarketBeat

Topics Artificial Intelligence Economy

Stock Market Rally At Highs; Taiwan Semi, ASML, Netflix In Focus: Weekly Review ↗

October 18, 2024

The Dow Jones and S&P 500 hit highs as they extended weekly win streaks.

Via Investor's Business Daily

Topics Stocks

Is Abbott Laboratories Stock a Buy? ↗

October 17, 2024

The healthcare stock is lagging the market this year.

Via The Motley Fool

Price Over Earnings Overview: Abbott Laboratories ↗

October 16, 2024

Via Benzinga

3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now ↗

October 18, 2024

These stocks could deliver big over the long term.

Via The Motley Fool

Abbott Labs Path to Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic ↗

October 17, 2024

Abbott Laboratories reported Q3 sales of $10.64 billion, driven by 8.2% organic growth in medical devices. Adjusted EPS for 2024 projected at $4.64-$4.70, with expectations of double-digit growth...

Via Benzinga

These Analysts Increase Their Forecasts On Abbott Laboratories After Better-Than-Expected Q3 Earnings ↗

October 17, 2024

Via Benzinga

AbbVie Is Doing 'Very Well' But Jim Cramer's Favorite? Abbott Laboratories ↗

October 17, 2024

AbbVie Inc., which split from Abbott Laboratories remains more than a decade ago, is doing "very, very well," Jim Cramer says.

Via Benzinga

Meta To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Thursday ↗

October 17, 2024

Via Benzinga

Abbott Labs Earnings Edge Past Q3 Views, Led By Medical Devices ↗

October 16, 2024

Medical devices led organic sales growth.

Via Investor's Business Daily

A Glimpse of Abbott Laboratories's Earnings Potential ↗

October 15, 2024

Via Benzinga

Beyond The Numbers: 9 Analysts Discuss Abbott Laboratories Stock ↗

October 14, 2024

Via Benzinga

Why Abbott Laboratories Stock Was a Winner on Wednesday ↗

October 16, 2024

Investors bumped its shares higher following a decent, if unspectacular, earnings report.

Via The Motley Fool

Abbott Laboratories (ABT) Q3 2024 Earnings Call Transcript ↗

October 16, 2024

ABT earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Tech Stocks Stall, Small Caps Surge As Regional Banks Rally, Airlines Rocket: What's Driving Markets Wednesday? ↗

October 16, 2024

Small-cap stocks outperformed large caps in Wednesday's session, with the Russell 2000 Index surging to test July 2024 highs on the back of expectations for interest rate cuts and a strong rally in...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 16, 2024

Via Benzinga

A Look Into Abbott Laboratories Inc's Price Over Earnings ↗

October 08, 2024

Via Benzinga

US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results ↗

October 16, 2024

Via Benzinga

Abbott’s Growth and Dividends Make It a Smart Portfolio Pick

October 16, 2024

Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results align with the trend.

Via MarketBeat

Abbott Laboratories' Q3 Earnings: Revenue And EPS Beat, Company Says Well-Positioned To Achieve Upper End Of Annual Forecast ↗

October 16, 2024

Abbott Laboratories reported third-quarter 2024 sales of $10.64B, with Medical Devices leading 11.7% sales growth. Adjusted EPS of $1.21 beat analyst expectations. Full-year guidance was updated.

Via Benzinga

US Stocks Could Open Narrowly Mixed After Tuesday's Chip Sell-Off, Bitcoin Heads To $68K, Oil Slips ↗

October 16, 2024

U.S. stock futures point to a flattish start on Wednesday after the S&P 500 Index and the Dow Jones Industrial Average retreated from record highs in the previous session.

Via Benzinga

Topics Stocks

Abbott Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗

October 16, 2024

Via Benzinga

Nasdaq Dips 1% Amid Plunge In Chipmaker Stocks: Fear & Greed Index Moves To 'Greed' Zone ↗

October 16, 2024

Via Benzinga

Morgan Stanley, Abbott Laboratories And 3 Stocks To Watch Heading Into Wednesday ↗

October 16, 2024

Via Benzinga

Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce ↗

October 14, 2024

Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana.

Via Talk Markets

Columbus Day: Is Stock Market Open Today? ↗

October 14, 2024

Investors should brace for a busy week with earnings reports from major companies.

Via Benzinga

Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth ↗

October 08, 2024

Abbott Laboratories' MedTech portfolio currently contributes around 45% of total sales of about $42 billion.

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

50 51 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.